A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2029

Conditions

Metastatic Solid TumorBrain Metastases

Interventions

DRUG

Trastuzumab emtansine

Given by IV (vein)

DRUG

Tucatinib

Given by PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston